We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Proteomic Assessment of Preterm Birth (PAPR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01371019
Recruitment Status : Completed
First Posted : June 10, 2011
Last Update Posted : June 11, 2015
Information provided by (Responsible Party):
Sera Prognostics, Inc.

June 8, 2011
June 10, 2011
June 11, 2015
April 2011
December 2014   (Final data collection date for primary outcome measure)
Spontaneous Preterm Birth [ Time Frame: August 2015 ]
Not Provided
Complete list of historical versions of study NCT01371019 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Proteomic Assessment of Preterm Birth
Proteomic Assessment of Preterm Birth
The purpose of this study is to to collect and store blood samples that will be utilized to develop a multimarker test to predict preterm delivery.
Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Serum, plasma
Probability Sample
Pregnant women who are receiving prenatal care.
Preterm Birth
Not Provided
  • Women with preterm delivery
  • Women without preterm delivery
Esplin MS, Merrell K, Goldenberg R, Lai Y, Iams JD, Mercer B, Spong CY, Miodovnik M, Simhan HN, van Dorsten P, Dombrowski M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Proteomic identification of serum peptides predicting subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2011 May;204(5):391.e1-8. doi: 10.1016/j.ajog.2010.09.021. Epub 2010 Nov 11.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
April 2015
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is 18 years or older.
  • Subject has a singleton pregnancy.
  • Subject is able to provide consent.

Exclusion Criteria:

  • Subject is pregnant with more than one fetus.
  • There is a known or suspected fetal anomaly.
Sexes Eligible for Study: Female
18 Years to 60 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Sera - 004
Not Provided
Not Provided
Sera Prognostics, Inc.
Sera Prognostics, Inc.
Not Provided
Study Director: Durlin E Hickok, MD, MPH Sera Prognostics, Inc.
Sera Prognostics, Inc.
June 2015